| Company Name: |
WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd.
|
| Tel: |
17702719238 17702719238 |
| Email: |
sales@sun-shinechem.com |
| Products Intro: |
Product Name:Xanomeline tartrate
CAS:152854-19-8
Purity:98% HPLC Package:50.0mg;100.0mg; 200.0mg;500mg;1g;5g; 10g
|
LY 246708 tartrate manufacturers
- Xanomeline tartrate
-
- $30.00 / 2mg
-
2025-05-09
- CAS:152854-19-8
- Min. Order:
- Purity: 99.19%
- Supply Ability: 10g
|
| | LY 246708 tartrate Basic information |
| Product Name: | LY 246708 tartrate | | Synonyms: | LY 246708 tartrate;(+)-L-Hydrogen tartrate;Xanomeline tartrate;Sarnomil tartrate;Zhan Nuo Meilin Tartrate;3-(Hexyloxy)-4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazole (2R,3R)-2,3-dihydroxysuccinate | | CAS: | 152854-19-8 | | MF: | C18H29N3O7S | | MW: | 431.50376 | | EINECS: | | | Product Categories: | API | | Mol File: | 152854-19-8.mol |  |
| | LY 246708 tartrate Chemical Properties |
| Melting point | 95.5° | | storage temp. | -20°C | | solubility | Soluble in DMSO (45 mg/ml) or Water (70 mg/ml) | | form | solid | | color | Off-white | | Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or water may be stored at -20°C for up to 2 months. | | InChIKey | SJSVWTMVMBGIHQ-LREBCSMRSA-N |
| | LY 246708 tartrate Usage And Synthesis |
| Description | Xanomeline tartrate (152854-19-8) functionally-selective M1 muscarinic receptor agonist, EC50=0.3, 92.5, 5, 52 and 42 nM for M1, M2, M3, M4 and M5 respectively.1,2 Displays positive cognitive and behavioral effects in schizophrenia and Alzheimer’s disease.3 Suppresses proinflammatory cytokine responses and improves survival in sepsis.4 Displays potent analgesic activity in rodent models of chronic inflammatory and neuropathic pain.5 | | Uses | Alzheimer’s disease treatment (cholinergic agonist). | | in vivo | Xanomeline (LY 246708) (0.5-3 mg/kg; s.c.; 1-3 hours) induces salivation and vomiting in some monkeys[3].
?
Xanomeline (LY 246708) shows functional dopamine antagonism and an antipsychotic-like profile[3].
?
Xanomeline (LY 246708) inhibits D-amphetamine- and (?)-apomorphine-induced behavior and do not cause extrapyramidal side effects[3]. | Animal Model: | Male Cebus apella monkeys[3] | | Dosage: | 0.5-3 mg/kg | | Administration: | s.c.; 1-3 hours | | Result: | Induced salivation and vomiting in some monkeys. |
| | References | Heinrich et al. (2009), Pharmacological Comparison of Muscarininc Ligands: Historical Versus more Recent Muscarinic M1-preferring Receptor Agonists; Eur. J. Pharmacol., 605 53
Jakubik et al. (2008), Importance and prospects for design of selective muscarinic agonists; Physiol. Res., 57 Suppl. 3 S39
Bender et al. (2017), Classics in Chemical Neuroscience: Xanomeline; ACS Chem. Neurosci, 8 435
Rosas-Ballina et al. (2015), Xanomeline Suppresses Excessive Pro-Inflammatory Cytokine Responses Through Neural Signal-Mediated Pathways and Improves Survival in Lethal Inflammation; Brain Behav. Immun., 44 19
Martino et al. (2011), The M1/M4 Preferring Agonist Xanomeline Is Analgesic in Rodent Models of Chronic Inflammatory and Neuropathic Pain via Central Site of Action; Pain, 152 2852 |
| | LY 246708 tartrate Preparation Products And Raw materials |
|